R&D GLP-1s in CKD: Evidence, market leadership, and key insights... At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight.
R&D On CB1s as an alternative to GLP-1s, with Punit Dhillon In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.
R&D On inflammation, heart health, and GLP-1 possibilities, with... Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.
R&D Global pharmaceutical market projections through 2030 Global pharmaceutical market projections through 2030, with Norstella's Daniel Chancellor.
R&D A different approach to obesity treatment, with Steffen-Seba... At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.
R&D Six things we learned about the obesity market at LSX 2025 In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
